Alexis Oliva

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4627123/publications.pdf

Version: 2024-02-01

40 papers	628 citations	687363 13 h-index	610901 24 g-index
41 all docs	41 docs citations	41 times ranked	893 citing authors

#	Article	IF	Citations
1	Opioid use trends in Spain: the case of the island of La Gomera (2016â€“2019). Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 217-226.	3.0	5
2	Limitations of the quality range approach in analytical similarity assessment: Effect of mean shift and relative variability. Journal of Pharmaceutical and Biomedical Analysis, 2021, 198, 114017.	2.8	2
3	New Quality-Range-Setting Method Based on Between- and Within-Batch Variability for Biosimilarity Assessment. Pharmaceuticals, 2021, 14, 527.	3.8	1
4	Uncertainty of Size-Exclusion Chromatography Method in Quality Control of Bevacizumab Batches. Separations, 2021, 8, 133.	2.4	1
5	Validation of a Size-Exclusion Chromatography Method for Bevacizumab Quantitation in Pharmaceutical Preparations: Application in a Biosimilar Study. Separations, 2019, 6, 43.	2.4	8
6	Application of capability indices and control charts in the analytical method control strategy. Journal of Separation Science, 2017, 40, 3046-3053.	2.5	5
7	Development of an ultra high performance liquid chromatography method for determining triamcinolone acetonide in hydrogels using the design of experiments/design space strategy in combination with process capability index. Journal of Separation Science, 2016, 39, 2689-2701.	2.5	12
8	Pre-study and in-study validation of a size-exclusion chromatography method with different detection modes for the analysis of monoclonal antibody aggregates. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1022, 206-212.	2.3	8
9	Fitting bevacizumab aggregation kinetic data with the Finkeâ€“Watzky two-step model: Effect of thermal and mechanical stress. European Journal of Pharmaceutical Sciences, 2015, 77, 170-179.	4.0	16
10	Capability measurement of size-exclusion chromatography with a light-scattering detection method in a stability study of bevacizumab using the process capability indices. Journal of Chromatography A, 2014, 1353, 89-98.	3.7	13
11	Poly-(cyclo)dextrins as ethoxzolamide carriers in ophthalmic solutions and in contact lenses. Carbohydrate Polymers, 2013, 98, 1343-1352.	10.2	47
12	Development and validation of an UPLC method for determination of content uniformity in low-dose solid drugs products using the design space approach. Talanta, 2013, 115, 490-499.	5.5	10
13	An improved methodology for data analysis in accelerated stability studies of peptide drugs: Practical considerations. Talanta, 2012, 94, 158-166.	5.5	14
14	Data analysis in stability studies of biopharmaceutical drugs with isothermal and non-isothermal assays. TrAC - Trends in Analytical Chemistry, 2011, 30, 717-730.	11.4	5
15	In-vitro release of fluoropyrimidines from PLGA film implants. Journal of Pharmacy and Pharmacology, 2010, 54, 757-763.	2.4	21
16	Stability Study of Human Serum Albumin Pharmaceutical Preparations. Journal of Pharmacy and Pharmacology, 2010, 51, 385-392.	2.4	34
17	Anti-tumor effects of adenovirus containing human growth hormone sequences in a mouse model of human ovarian cancer. Endocrine, 2010, 37, 430-439.	2.3	3
18	Solid-state stability studies of cholecystokinin (CCK-4) peptide under nonisothermal conditions using thermal analysis, chromatography and mass spectrometry. European Journal of Pharmaceutical Sciences, 2010, 39, 263-271.	4.0	6

#	Article	IF	Citations
19	Application of a validated stability-indicating chromatographic method to evaluate the reproducibility between batches of small peptides in solution. Analytica Chimica Acta, 2010, 675, 83-90.	5.4	1
20	Evaluation of non-isothermal methods in stability studies of human insulin pharmaceutical preparations. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 916-922.	2.8	6
21	Estimation of uncertainty in size-exclusion chromatography with a double detection system (light-scattering and refractive index). Talanta, 2009, 78, 781-789.	5.5	6
22	New Trends in Analysis of Biopharmaceutical Products. Current Pharmaceutical Analysis, 2007, 3, 230-248.	0.6	19
23	Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and hydrogen exchange combined with enzymatic digestion for the structural characterization of antimalaric Spf66 peptide. Talanta, 2007, 72, 1192-1198.	5.5	2
24	Evaluation of Cholecystokinin (CCK-8) Peptide Thermal Stability for Use as Radiopharmaceutical by Means Isothermal and Nonisothermal Approaches. Drug Development and Industrial Pharmacy, 2006, 32, 947-953.	2.0	5
25	New administration model of trans-chalcone biodegradable polymers for the treatment of experimental leishmaniasis. Acta Tropica, 2006, 98, 59-65.	2.0	36
26	A mathematical model for interpreting in vitro rhGH release from laminar implants. International Journal of Pharmaceutics, 2006, 309, 38-43.	5.2	11
27	Data Analysis of Kinetic Modelling Used in Drug Stability Studies: Isothermal Versus Nonisothermal Assays. Pharmaceutical Research, 2006, 23, 2595-2602.	3.5	17
28	Measurement of uncertainty in peptide molecular weight determination using size-exclusion chromatography with multi-angle laser light-scattering detection and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Analytica Chimica Acta, 2004, 512, 103-110.	5.4	12
29	Stability Indicating Method for SPf66 Antimalarial Peptide in Solution. Drug Development and Industrial Pharmacy, 2004, 30, 389-395.	2.0	0
30	Applications of Multi-Angle Laser Light-Scattering Detection in the Analysis of Peptides and Proteins. Current Drug Discovery Technologies, 2004, 1, 229-242.	1.2	32
31	Effect of high shear rate on stability of proteins: kinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2003, 33, 145-155.	2.8	50
32	Comparison of Shelf-Life Estimates for a Human Insulin Pharmaceutical Preparation Using the Matrix and Full-Testing Approaches. Drug Development and Industrial Pharmacy, 2003, 29, 513-521.	2.0	2
33	APPLICATION OF THE ICH GUIDELINES IN VALIDATION OF A CHROMATOGRAPHIC METHOD FOR CCK-4 FRAGMENT OF CHOLECYSTOKININ. Journal of Liquid Chromatography and Related Technologies, 2002, 25, 2795-2806.	1.0	0
34	Characterization of antimalarial SPf66 peptide using MALDIâ€“TOF MS, CD and SEC. Peptides, 2002, 23, 1527-1535.	2.4	4
35	Chromatographic characterization of synthetic peptides: SPf66 malaria vaccine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 766, 3-12.	2.3	13
36	Comparative study of protein molecular weights by size-exclusion chromatography and laser-light scattering. Journal of Pharmaceutical and Biomedical Analysis, 2001, 25, 833-841.	2.8	53

#	Article	IF	Citations
37	Development of two high-performance liquid chromatographic methods for the analysis and characterization of insulin and its degradation products in pharmaceutical preparations. Biomedical Applications, 2000, 749, 25-34.	1.7	91
38	Statistical assessment of between batch stability equivalence. International Journal of Pharmaceutics, 2000, 204, 61-68.	5.2	3
39	Influence of temperature and shaking on stability of insulin preparations: Degradation kinetics. International Journal of Pharmaceutics, 1996, 143, 163-170.	5.2	53
40	Combining Capability Indices and Control Charts in the Process and Analytical Method Control Strategy. , 0, , .		1